Table 6 Additional sensitivity analysis comparing use of 1 or 2 placebo periods for the primary analysis
Placebo-corrected adjusted means and 90% CIs for the mean QTcN change from baseline 1−4 hours after dosing analysed using two different ANCOVA models | ||||
|---|---|---|---|---|
ANCOVA model | 25Â mg empagliflozin Difference from placebo, ms | 200Â mg empagliflozin Difference from placebo, ms | ||
| Â | Mean (SE) | 90% CI | Mean (SE) | 90% CI |
Primary analysis model with placebo period 1 only | 0.2 (0.9) | (-1.4, 1.8) | -0.5 (0.8) | (-1.8, 0.8) |
Primary analysis model with placebo period 2 only | 0.6 (1.0) | (-1.2, 2.4) | 0.1 (0.8) | (-1.4, 1.5) |